233 related articles for article (PubMed ID: 32191360)
21. Hormonal contraceptive use before hCG remission does not increase the risk of gestational trophoblastic neoplasia following complete hydatidiform mole: a historical database review.
Braga A; Maestá I; Short D; Savage P; Harvey R; Seckl MJ
BJOG; 2016 Jul; 123(8):1330-5. PubMed ID: 26444183
[TBL] [Abstract][Full Text] [Related]
22. MicroRNA Expression Profiling in Hydatidiform Mole for the Prediction of Postmolar GTN : MicroRNA Profile in Postmolar GTN.
Teerapakpinyo C; Areeruk W; Tantbirojn P; Phupong V; Shuangshoti S; Lertkhachonsuk R
Technol Cancer Res Treat; 2022; 21():15330338211067309. PubMed ID: 35023789
[No Abstract] [Full Text] [Related]
23. Does a human chorionic gonadotropin level of over 20,000 IU/L four weeks after uterine evacuation for complete hydatidiform mole constitute an indication for chemotherapy for gestational trophoblastic neoplasia?
Braga A; Biscaro A; do Amaral Giordani JM; Viggiano M; Elias KM; Berkowitz RS; Seckl MJ
Eur J Obstet Gynecol Reprod Biol; 2018 Apr; 223():50-55. PubMed ID: 29477553
[TBL] [Abstract][Full Text] [Related]
24. Women with a partial mole during their first pregnancy and diagnosed earlier in gestation are at increased risk of developing gestational trophoblastic neoplasia.
Worley MJ; Joseph NT; Berkowitz RS; Goldstein DP
Int J Gynecol Cancer; 2014 Jun; 24(5):941-5. PubMed ID: 24819660
[TBL] [Abstract][Full Text] [Related]
25. Genetics of gestational trophoblastic disease.
Fisher RA; Maher GJ
Best Pract Res Clin Obstet Gynaecol; 2021 Jul; 74():29-41. PubMed ID: 33685819
[TBL] [Abstract][Full Text] [Related]
26. Auxiliary and experimental diagnostic techniques for hydatidiform moles.
Usui H
J Obstet Gynaecol Res; 2022 Dec; 48(12):3077-3086. PubMed ID: 36098274
[TBL] [Abstract][Full Text] [Related]
27. Incidence of postmolar gestational trophoblastic disease in androgenetic moles and the morphological features associated with low risk postmolar gestational trophoblastic disease.
Kaneki E; Kobayashi H; Hirakawa T; Matsuda T; Kato H; Wake N
Cancer Sci; 2010 Jul; 101(7):1717-21. PubMed ID: 20518791
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of a routine second curettage for hydatidiform mole: a cohort study.
Yamamoto E; Nishino K; Niimi K; Watanabe E; Oda Y; Ino K; Kikkawa F
Int J Clin Oncol; 2020 Jun; 25(6):1178-1186. PubMed ID: 32144509
[TBL] [Abstract][Full Text] [Related]
29. Clinical Features of Gestational Trophoblastic Disease in Aged Women in South Vietnam.
Nguyen BQ; Vo TM; Phan VTT; Nguyen C; Vu H; Vo B
Yonsei Med J; 2023 Apr; 64(4):284-290. PubMed ID: 36996900
[TBL] [Abstract][Full Text] [Related]
30. Proteomic identification of predictive biomarkers for malignant transformation in complete hydatidiform moles.
Vanichtantikul A; Hodge KG; Somparn P; Saethang T; Triratanachat S; Pisitkun T; Lertkhachonsuk R
Placenta; 2019 Feb; 77():58-64. PubMed ID: 30827356
[TBL] [Abstract][Full Text] [Related]
31. Centralized surveillance of hydatidiform mole: 7-year experience from a regional hospital in China.
Jiao L; Wang Y; Jiang J; Wang X; Zhang W; Zhu C; Xiang Y
Int J Gynecol Cancer; 2022 Feb; 32(2):147-152. PubMed ID: 34799419
[TBL] [Abstract][Full Text] [Related]
32. Influence of COVID-19 pandemic on molar pregnancy and postmolar gestational trophoblastic neoplasia: An observational study.
Campos V; Paiva G; Padron L; Freitas F; Pedrotti LG; Sun SY; Viggiano M; Oliveira L; Rohr L; Madi JM; Arrym TP; Oliveira P; Dos Santos Esteves APV; Junior JA; Filho JR; Elias KM; Horowitz NS; Braga A; Berkowitz RS
BJOG; 2023 Feb; 130(3):292-302. PubMed ID: 36209485
[TBL] [Abstract][Full Text] [Related]
33. Expression of maspin in gestational trophoblastic disease.
Li HW; Leung SW; Cheung AN; Yu MM; Chan LK; Wong YF
Gynecol Oncol; 2006 Apr; 101(1):76-81. PubMed ID: 16271752
[TBL] [Abstract][Full Text] [Related]
34. Parental contribution to trisomy in heterozygous androgenetic complete moles.
Usui H; Sato A; Shozu M
Sci Rep; 2020 Oct; 10(1):17137. PubMed ID: 33051545
[TBL] [Abstract][Full Text] [Related]
35. Clinical Presentation of Complete Hydatidiform Mole and Partial Hydatidiform Mole at a Regional Trophoblastic Disease Center in the United States Over the Past 2 Decades.
Sun SY; Melamed A; Joseph NT; Gockley AA; Goldstein DP; Bernstein MR; Horowitz NS; Berkowitz RS
Int J Gynecol Cancer; 2016 Feb; 26(2):367-70. PubMed ID: 26588240
[TBL] [Abstract][Full Text] [Related]
36. Presentation, medical complications and development of gestational trophoblastic neoplasia of hydatidiform mole after intracytoplasmic sperm injection as compared to hydatidiform mole after spontaneous conception - a retrospective cohort study and literature review.
Braga A; Andrade T; do Carmo Borges de Souza M; Campos V; Freitas F; Maestá I; Sun SY; Pedrotti LG; Bessel M; Junior JA; Filho JR; Elias KM; Horowitz NS; Berkowitz RS
Gynecol Oncol; 2023 Mar; 170():179-185. PubMed ID: 36706644
[TBL] [Abstract][Full Text] [Related]
37. Risk factors for gestational trophoblastic neoplasia development of singleton normal fetus with partial hydatidiform mole pregnancy: A retrospective cohort and literature review.
Zhong L; Song L; Yin R; Li Q; Wang D
J Obstet Gynaecol Res; 2023 Feb; 49(2):479-486. PubMed ID: 36328803
[TBL] [Abstract][Full Text] [Related]
38. Heterozygous/dispermic complete mole confers a significantly higher risk for post-molar gestational trophoblastic disease.
Zheng XZ; Qin XY; Chen SW; Wang P; Zhan Y; Zhong PP; Buza N; Jin YL; Wu BQ; Hui P
Mod Pathol; 2020 Oct; 33(10):1979-1988. PubMed ID: 32404958
[TBL] [Abstract][Full Text] [Related]
39. Epidemiology of gestational trophoblastic diseases.
Steigrad SJ
Best Pract Res Clin Obstet Gynaecol; 2003 Dec; 17(6):837-47. PubMed ID: 14614884
[TBL] [Abstract][Full Text] [Related]
40. Epidemiology of Hydatidiform Moles in a Tertiary Hospital in Thailand over Two Decades: Impact of the National Health Policy.
Wairachpanich V; Limpongsanurak S; Lertkhachonsuk R
Asian Pac J Cancer Prev; 2015; 16(18):8321-5. PubMed ID: 26745079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
